Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1877751 | 0.94 | LMNA (0.34) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL1878741 | 0.91 | TP53 (0.35) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL1880834 | 0.89 | LMNA (0.36) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL1880437 | 0.87 | HPGD (0.37) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL1872899 | 0.84 | TP53 (0.34) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL1884190 | 0.82 | CA2 (0.39) | LMNASMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL1044349 | 0.79 | HTR1A (0.40) | CA2HPGDALOX5 | |
| SCHEMBL15864983 | 0.79 | HTR1A (0.40) | CA2HPGDALOX5 | |
| SCHEMBL1879143 | 0.79 | CA2 (0.42) | SMN1; SMN2CA2HPGD | |
| SCHEMBL1876054 | 0.78 | CA2 (0.44) | CA2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | claimed |
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | LMNA 4504/4885SMN1; SMN2 689/4885MEN1 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.